Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.
OBESITY RESEARCH SOLUTIONSBRD3308 is an inhibitor of histone deacetylase 3 (HDAC3; Ki = 29 nM).1 It is selective for HDAC3 over HDAC1 and HDAC2 (Kis = 6,300 and 5,100 nM, respectively). BRD3308 (10 µM) reduces cytokine-induced increases in apoptosis in rat INS-1E β cells. In vivo, BRD3308 (5 mg/kg) reduces plasma glucose levels in rats and increases plasma insulin levels in rats in a hyperglycemic clamp assay as a model of type 2 diabetes.2
WARNING This product is not for human or veterinary use.
1. An Isochemogenic Set of Inhibitors To Define the Therapeutic Potential of Histone Deacetylases in β-
2. Histone deacetylase 3 inhibition improves glycaemia and insulin secretion in obese diabetic rats. Diabetes Obes. Metab. 17(7), 703-707 (2015).